Payment overview · 2025
General Payments
$566.57
40 reported records · 7 companies
Healthcare provider profile · identity verified
William J Martin, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORTH CONWAY, NH · NPI 1215115639
Verified facts
What the public records show
CMS Open Payments records show William J Martin, MD received $566.57 in general payments during 2025 across 40 reported records.
ABBVIE INC. accounted for 59.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $337.30 | 59.5% | 27 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.82 | 18.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.39 | 7.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.17 | 4.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.67 | 4.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.27 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.95 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $566.57 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $142.49 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $137.01 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $109.08 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $75.07 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $57.80 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $44.72 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.39 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.39 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.75 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 243 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 54 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
262 | 74 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
243 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
182 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 531 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 475 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 469 | 162 |
| Pantoprazole Sodium | Pantoprazole Sodium | 465 | 156 |
| Losartan Potassium | Losartan Potassium | 457 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 441 | 162 |
| Montelukast Sodium | Montelukast Sodium | 401 | 123 |
| Gabapentin | Gabapentin | 379 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 99 |
| Omeprazole | Omeprazole | 267 | 92 |
| Jardiance | Empagliflozin | 262 | 74 |
| Mounjaro | Tirzepatide | 243 | 44 |
| Trazodone Hcl | Trazodone Hcl | 227 | 72 |
| Furosemide | Furosemide | 215 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 209 | 69 |
| Diclofenac Sodium | Diclofenac Sodium | 208 | 71 |
| Eliquis | Apixaban | 182 | 68 |
| Celecoxib | Celecoxib | 177 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 172 | 55 |
| Prednisone | Prednisone | 167 | 118 |
| Lisinopril | Lisinopril | 164 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 59 |
| Carvedilol | Carvedilol | 150 | 53 |
| Metformin Hcl | Metformin Hcl | 140 | 45 |
| Potassium Chloride | Potassium Chloride | 134 | 47 |
| Nifedipine Er | Nifedipine | 132 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 128 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 50 |
| Bumetanide | Bumetanide | 118 | 41 |
| Pregabalin | Pregabalin | 107 | 28 |
| Meloxicam | Meloxicam | 97 | 40 |
| Spironolactone | Spironolactone | 97 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 95 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 93 | 78 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 92 | 74 |
| Simvastatin | Simvastatin | 81 | 20 |
| Bupropion Xl | Bupropion Hcl | 80 | 21 |
| Alprazolam | Alprazolam | 74 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 23 |
| Allopurinol | Allopurinol | 72 | 24 |
| Synthroid | Levothyroxine Sodium | 72 | 19 |
| Valsartan | Valsartan | 71 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 26 |
| Trulicity | Dulaglutide | 68 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 13 |
| Clonazepam | Clonazepam | 64 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 23 |
| Famotidine | Famotidine | 62 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 19 |
| Meclizine Hcl | Meclizine Hcl | 59 | 29 |
| Ondansetron Odt | Ondansetron | 58 | 40 |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 15 |
| Tramadol Hcl | Tramadol Hcl | 57 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 15 |
| Rybelsus | Semaglutide | 54 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 14 |
| Ezetimibe | Ezetimibe | 53 | 26 |
| Metformin Hcl Er | Metformin Hcl | 53 | 15 |
| Ozempic | Semaglutide | 53 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 25 |
| Glipizide | Glipizide | 52 | 18 |
| Linzess | Linaclotide | 52 | 17 |
| Fenofibrate | Fenofibrate | 51 | 14 |
| Glimepiride | Glimepiride | 51 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 45 |
| Finasteride | Finasteride | 50 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | 15 |
| Fluconazole | Fluconazole | 44 | 34 |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | 13 |
| Januvia | Sitagliptin Phosphate | 43 | 13 |
| Cephalexin | Cephalexin | 42 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 16 |
| Nystatin | Nystatin | 42 | 24 |
| Ibuprofen | Ibuprofen | 41 | 21 |
| Mirtazapine | Mirtazapine | 40 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 13 |
| Tradjenta | Linagliptin | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 11 |
| Colchicine | Colchicine | 39 | 13 |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Sucralfate | Sucralfate | 37 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Irbesartan | Irbesartan | 35 | 13 |
| Ketoconazole | Ketoconazole | 35 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | 13 |
| Glipizide Er | Glipizide | 32 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | 12 |
| Clonidine Hcl | Clonidine Hcl | 29 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 15 |
| Digoxin | Digoxin | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Febuxostat | Febuxostat | 24 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | 14 |
| Levetiracetam | Levetiracetam | 23 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | 13 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Prolia | Denosumab | 21 | 15 |
| Torsemide | Torsemide | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 11 |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Lipitor | Atorvastatin Calcium | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Topiramate Er | Topiramate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Klonopin | Clonazepam | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $566.57 · 40 records | ABBVIE INC. | CREON, Dexcom G6 Transmitter, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error